Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan OKs FY2020 Budget, Record 35.86 Trillion Yen Allotted to Social Security
The Japanese government on December 20 approved a record general account budget of 102.66 trillion yen for FY2020 beginning next April, which includes social security budgets totaling 35.86 trillion yen, also an all-time high. The social security budgets, which not…
To read the full story
Related Article
- Japan to Shave Drug Spending by 4.38% in FY2020 Price Revision: MHLW
December 20, 2019
- FY2020 Drug Price Revision to Shed 110 Billion Yen in Central Govt Spending
December 18, 2019
REGULATORY
- Yaz, Actemra Indications Deemed High-Need by MHLW Panel
September 7, 2026
- Minister Defends Scope of Low-Income Exemption for OTC-Like Drug Charge
September 7, 2026
- LDP Panel Chief Calls for Earlier CGP Coverage in Cancer Care
September 4, 2026
- Japan to Revisit Handling of Steroid Creams under OTC-Like Drug Charge
September 4, 2026
- UK Halts Tavneos for New Patients, Approval Revocation Set for March
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…